Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine-ER 5mg vs 10mg in MS
NCT01328379Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- Mar 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS) (3 arms), sponsored by Acorda Therapeutics. Primary endpoint: Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State at 4 weeks. Started Mar 2011; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01328379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01328379.